Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Applied Therapeutics Inc. (APLT : NSDQ)

• Company Description    Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing drug candidates for unmet medical need. The company's product candidate consists of AT-001, for the treatment of Diabetic Cardiomyopathy; AT-007, for the treatment of Galactosemia and AT-003, for the treatment of diabetic retinopathy which are in clinical stage. Applied Therapeutics Inc. is based in New York, United States. Number of Employees: 34

• Price / Volume Information    Yesterday's Closing Price: $1.52 Daily Weekly Monthly 20 Day Moving Average: 159,820 shares Shares Outstanding: 26.24 (millions) Market Capitalization: $39.88 (millions) Beta: 1.52 52 Week High: $25.59 52 Week Low: $1.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -25.12% -15.66% 12 Week -22.05% -14.30% Year To Date -83.02% -79.25%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 545 5TH AVENUE SUITE 1400 - NEW YORK,NY 10017 USA ph: 212-220-9226 fax: - maeve@argotpartners.com http://www.appliedtherapeutics.com

• General Corporate Information    Officers Shoshana Shendelman - Chair of the Board President and Chief Executive O Chids Mahadevan - Senior Vice President of Finance Steven Ortega - Chief Accounting Officer Les Funtleyder - Director Teena Lerner - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03828A101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 26.24 Most Recent Split Date: (:1) Beta: 1.52 Market Capitalization: $39.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.46 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.95 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 12.00% vs. Previous Quarter: 15.38% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -137.70 12/31/21 - -106.41 09/30/21 - -98.12 ROA 03/31/22 - -101.89 12/31/21 - -84.19 09/30/21 - -79.12 Current Ratio 03/31/22 - 2.86 12/31/21 - 3.34 09/30/21 - 3.79 Quick Ratio 03/31/22 - 2.86 12/31/21 - 3.34 09/30/21 - 3.79 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.60 12/31/21 - 2.39 09/30/21 - 3.31 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©